Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down – Here’s Why

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price gapped down prior to trading on Monday. The stock had previously closed at $49.83, but opened at $47.89. Pulse Biosciences shares last traded at $48.6050, with a volume of 19,462 shares trading hands.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Mizuho set a $45.00 price target on shares of Pulse Biosciences in a report on Monday, August 10th. Wall Street Zen raised Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. Canaccord Genuity Group boosted their price objective on Pulse Biosciences from $43.00 to $58.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Finally, Freedom Capital raised Pulse Biosciences to a “strong-buy” rating in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pulse Biosciences has an average rating of “Moderate Buy” and an average target price of $53.20.

Pulse Biosciences Trading Down 1.5%

The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of -42.16 and a beta of 1.57. The firm’s 50-day moving average is $47.99 and its 200 day moving average is $32.88.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. Analysts predict that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Transactions at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky purchased 1,036 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was purchased at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer owned 1,036 shares in the company, valued at approximately $49,966.28. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 4,095 shares of company stock valued at $199,931 in the last quarter. 74.00% of the stock is owned by insiders.

Institutional Trading of Pulse Biosciences

Hedge funds have recently modified their holdings of the stock. Osterweis Capital Management Inc. purchased a new position in Pulse Biosciences during the second quarter worth about $28,000. Jupiter Topco LLC bought a new position in shares of Pulse Biosciences during the 2nd quarter worth $241,000. GSA Capital Partners LLP purchased a new position in shares of Pulse Biosciences in the second quarter worth about $290,000. Legal & General Group Plc bought a new stake in Pulse Biosciences during the 2nd quarter valued at $395,000. Finally, Cetera Investment Advisers bought a new stake in shares of Pulse Biosciences during the 1st quarter valued at $387,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue.

The company’s lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology.